Virtual Library

Start Your Search

A. Gamboni



Author of

  • +

    P1.02 - Poster Session with Presenters Present (ID 454)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Biology/Pathology
    • Presentations: 1
    • +

      P1.02-005 - Frequency of Actionable Alterations in EGFR wt NSCLC: Experience of the Wide Catchment Area of Romagna (AVR) (ID 3934)

      14:30 - 15:45  |  Author(s): A. Gamboni

      • Abstract
      • Slides

      Background:
      Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors have improved the outcome of patients with EGFR-mutated lung adenocarcinoma (ADC). However, EGFR mutation occurred in about only 10-15% of ADC, but other alterations are emerging as potential target of drugs. We analyzed the frequency of potentially targetable driver alterations in a series of advanced EGFR-wild type (wt) NSCLC patients.

      Methods:
      724 advanced EGFR-wt NSCLC patients enrolled from the Wide Catchment Area of Romagna (AVR) between January 2013 to December 2014 were included in the study. KRAS, BRAF, ERBB2, PIK3CA, NRAS, ALK, MAP2K1, RET and DDR2 mutations were analyzed by Myriapod[®]Lung Status kit (Diatech Pharmacogenetics) on MassARRAY[®] (SEQUENOM[®] Inc, California). ERBB4 was evaluated by direct sequencing and EML4-ALK and ROS1 rearrangements were assessed by immunohistochemistry or fluorescence in situ hybridization.

      Results:
      331 (45.7%) patients showed at least one alteration. Of these, 72.2%, 6.3%, 3.6%, 1.8%, 2.1% and 1.2% patients had mutations in KRAS, BRAF, PIK3CA, NRAS, ERBB2 and MAP2K1 genes, respectively. Only one patient showed a mutation in ERBB4 gene. EML4-ALK and ROS1 rearrangements were observed in 4.3% and 1.4% of all patients, respectively. The distribution of mutations in relation to gender and smoking habits is reported in the Table. Overlapping mutations were observed in 7 KRAS-mutated patients: 2 (28.6%) patients were also mutated in PIK3CA, 4 (57.1%) showed also an EML4- ALK translocation and one (14.3%) had a ROS1 rearrangement. One (0.3%) patient showed both BRAF and PIK3CA alterations. Correlation analyses between the different mutations and patient outcome are ongoing.

      GENE Mutated Patients N (%) Gender Smoking Habits*
      Female (%) Male (%) Smoker (%) Never Smoker (%)
      KRAS 239 (33) 93 (39) 146 (61) 115 (48.1) 9 (3.8)
      BRAF 21 (3) 11 (52.4) 10 (47.6) 11 (52.4) 1 (4.8)
      NRAS 6 (0.8) 4 (66.7) 2 (33.3) 4 (66.7) -
      PIK3CA 12 (1.6) 4 (33.3) 8 (66.7) 5 (41.7) -
      MAP2K1 4 (0.5) - 4 (100) 1 (25) -
      ERBB2 7 (0.9) 5 (71.4) 2 (28.6) - 1 (14.3)
      EML4-ALK 31 (4.3) 20 (64.5) 11 (35.5) 12 (38.7) 8 (25.8)
      ROS1 10 (1.4) 7 (70) 3 (30) 3 (30) 5 (50)
      *: some data are missing

      Conclusion:
      Driver mutations were detected in about 50% of EGFR wt lung ADC patients. Such alterations could represent potential targets for therapy and could be evaluated in routine multiplexed testing to obtain a wider tumor molecular characterization.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P3.02b - Poster Session with Presenters Present (ID 494)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P3.02b-006 - Role of TP53 Mutations in Determining Primary Resistance to First-Line Tyrosine Kinase Inhibitors in EGFR-Mutated NSCLC Patients (ID 3861)

      14:30 - 15:45  |  Author(s): A. Gamboni

      • Abstract
      • Slides

      Background:
      Patients with non-small-cell lung cancer (NSCLC) carrying specific mutations at epidermal growth factor receptor (EGFR) gene are usually sensitive to treatments with tyrosine kinase inhibitors (TKIs). However, not all EGFR-mutated patients respond equally to TKI treatments, and approximately 20-30% show primary resistance. Although the mechanisms responsible for acquired resistance are known, those responsible for primary resistance are not completely understood. In this study we aimed to assess the role of TP53 mutations in a cohort of advanced EGFR-mutated NSCLC patients receiving first-line TKIs. We analyzed TP53 gene status in relation to outcome in terms of overall response rate, disease control rate (DCR), response duration, progression free survival (PFS) and overall survival (OS).

      Methods:
      We retrospectively analyzed 136 patients with advanced EGFR-mutated NSCLC treated with first-line TKIs from January 2012 to April 2015. Exons 5-8 of TP53 gene were amplified by PCR and sequenced by direct sequencing on 123 patients. DCR was defined as the sum of complete response, partial response and stable disease. The survival endpoints examined were PFS and OS. PFS was defined as the time from start of first-line treatment to disease progression or death, whichever occurred first. OS was defined as the time from start of first-line treatment to death.

      Results:
      TP53 mutations were observed in 37 (30.1%) patients:10 (27.0%), 6 (16.2%), 9 (24.3%) and 12 (32.4%) in exons 5, 6, 7 and 8, respectively. DCR was 70% in TP53-mutated patients compared to 88% in TP53-wt patients (relative risk, RR: 3.17 [95% CI 1.21-8.48], p=0.019). In particular, a 42% DCR was observed in patients with TP53 exon 8 mutation compared to 87% in exon 8 wt patients (RR 9.6 [2.71-36.63], p<0.001). Shorter median PFS and OS were observed in patients with TP53 exon 8 mutations compared to other patients (4.2 months vs 12.5 months [p=0.058] and 16.2 months vs 32.3 months [p=0.114], respectively); these differences became significant in the subgroup of patients with EGFR exon 19 deletion (4.2 months vs 16.8 months [p<0.001] and 7.6 months vs not reached [p=0.006], respectively), hazard ratio (HR) 6.99 (95% CI 2.34-20.87, p<0.001) and HR 4.75 (95% CI 1.38-16.29, p=0.013), respectively.

      Conclusion:
      TP53 mutations, in particular exon 8 mutations and those defined as nondisruptive, reduce responsiveness to TKI treatment and induce a worse prognosis in EGFR-mutated NSCLC patients, especially in those carrying exon 19 deletions.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.